Lessons from COVID-19 to increase opioid vaccine acceptance

Publication type:
Journal article
Metadata:
Autoren
Autoren-URL
https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=fis-test-1&SrcAuth=WosAPI&KeyUT=WOS:000890799600003&DestLinkType=FullRecord&DestApp=WOS_CPL
DOI
10.1016/j.tips.2022.08.010
eISSN
1873-3735
Externe Identifier
  • Clarivate Analytics Document Solution ID: 6P2YG
  • PubMed Identifier: 36123169
ISSN
0165-6147
Ausgabe der Veröffentlichung
12
Zeitschrift
TRENDS IN PHARMACOLOGICAL SCIENCES
Paginierung
998 - 1000
Datum der Veröffentlichung
2022
Status
Published
Titel
Lessons from COVID-19 to increase opioid vaccine acceptance
Sub types
  • Editorial Material
Ausgabe der Zeitschrift
43

Data source: Web of Science (Lite)

Other metadata sources:
Autoren
DOI
10.1016/j.tips.2022.08.010
ISSN
0165-6147
Ausgabe der Veröffentlichung
12
Zeitschrift
Trends in Pharmacological Sciences
Sprache
en
Paginierung
998 - 1000
Datum der Veröffentlichung
2022
Status
Published
Herausgeber
Elsevier BV
Herausgeber URL
http://dx.doi.org/10.1016/j.tips.2022.08.010
Datum der Datenerfassung
2023
Titel
Lessons from COVID-19 to increase opioid vaccine acceptance
Ausgabe der Zeitschrift
43

Data source: Crossref

Abstract
COVID-19 has put vaccine efficacy under a spotlight. However, the reluctance of people to be vaccinated has postponed the end of the COVID-19 pandemic. Currently, opioid vaccines are being developed, which could help prevent opioid addiction, overdoses, or relapse in combination with medication-assisted therapy. The fear is that the uptake of opioid vaccines could be met by the same reluctance as seen with COVID-19 vaccines.
Addresses
  • Department of Pharmaceutical Biology, Institute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg University, Staudinger Weg 5, Mainz, Germany.
Autoren
DOI
10.1016/j.tips.2022.08.010
eISSN
1873-3735
Externe Identifier
  • PubMed Identifier: 36123169
  • PubMed Central ID: PMC9448697
Funding acknowledgements
  • Deutsche Forschungsgemeinschaft: DFG GRK2015/2
Open access
true
ISSN
0165-6147
Ausgabe der Veröffentlichung
12
Zeitschrift
Trends in pharmacological sciences
Schlüsselwörter
  • Humans
  • Analgesics, Opioid
  • Vaccines
  • Pandemics
  • COVID-19
  • COVID-19 Vaccines
Sprache
eng
Medium
Print-Electronic
Online publication date
2022
Open access status
Open Access
Paginierung
998 - 1000
Datum der Veröffentlichung
2022
Status
Published
Datum der Datenerfassung
2022
Titel
Lessons from COVID-19 to increase opioid vaccine acceptance.
Sub types
  • Research Support, Non-U.S. Gov't
  • review-article
  • Journal Article
Ausgabe der Zeitschrift
43

Files

https://europepmc.org/articles/PMC9448697?pdf=render

Data source: Europe PubMed Central

Abstract
COVID-19 has put vaccine efficacy under a spotlight. However, the reluctance of people to be vaccinated has postponed the end of the COVID-19 pandemic. Currently, opioid vaccines are being developed, which could help prevent opioid addiction, overdoses, or relapse in combination with medication-assisted therapy. The fear is that the uptake of opioid vaccines could be met by the same reluctance as seen with COVID-19 vaccines.
Date of acceptance
2022
Autoren
Autoren-URL
https://www.ncbi.nlm.nih.gov/pubmed/36123169
DOI
10.1016/j.tips.2022.08.010
eISSN
1873-3735
Externe Identifier
  • PubMed Central ID: PMC9448697
Ausgabe der Veröffentlichung
12
Zeitschrift
Trends Pharmacol Sci
Schlüsselwörter
  • COVID-19 vaccination
  • opioid misuse
  • opioid vaccination
  • public health
  • vaccine reluctance
  • Humans
  • COVID-19
  • COVID-19 Vaccines
  • Pandemics
  • Analgesics, Opioid
  • Vaccines
Sprache
eng
Country
England
Paginierung
998 - 1000
PII
S0165-6147(22)00196-1
Datum der Veröffentlichung
2022
Status
Published
Datum, an dem der Datensatz öffentlich gemacht wurde
2022
Titel
Lessons from COVID-19 to increase opioid vaccine acceptance.
Sub types
  • Journal Article
  • Research Support, Non-U.S. Gov't
Ausgabe der Zeitschrift
43

Data source: PubMed

Beziehungen:
Property of

Tools